Moderna mRNA Flu Vaccine Receives FDA Approval, Overcoming Half-Century Limits of Egg-Based Cultivation to Accelerate Response to Variants
Background
Seasonal influenza, which claims up to 650,000 lives globally each year, has long relied on vaccination as the best preventive measure. However, existing vaccine production systems possessed structural vulnerabilities, failing to keep pace with the rapid mutation rate of viruses. The egg-based cultivation method, used since the 1940s, requires approximately six months for the manufacturing process alone. A time lag occurs between the World Health Organization (WHO) announcing predicted circulating strains and the completion of production, frequently leading to a mismatch between circulating viruses and vaccine strains.
The issue of 'egg adaptation'—where genetic mutations occur as the virus multiplies inside the egg—was also a major cause of reduced vaccine efficacy. In practice, the actual effectiveness of seasonal flu vaccines has remained at levels of 40–60% depending on the year. Limitations in the distribution network were also pointed out, as large-scale vaccine production itself could be threatened if the supply of eggs from laying hens became unstable due to the spread of avian influenza. This is the background for why infectious disease experts have consistently called for a platform transition that allows for rapid design changes and carries a lower risk of mutation.
Key Findings
The U.S. Food and Drug Administration (FDA) has granted marketing approval for Moderna’s messenger ribonucleic acid (mRNA)-based influenza vaccine, mRNA-1010. This marks the moment when the mRNA platform, which demonstrated clinical utility during the COVID-19 pandemic, officially entered the mainstream respiratory disease area of seasonal flu. In the pivotal Phase 3 clinical trial that served as the core basis for approval, mRNA-1010 demonstrated significant immunogenicity compared to existing standard inactivated influenza vaccines in tens of thousands of adults.
mRNA-1010 encapsulates the hemagglutinin (HA) protein genetic sequences targeting Influenza A strains (H1N1, H3N2) and Influenza B strains (Victoria, Yamagata lineages) within lipid nanoparticles (LNPs). Clinical analysis showed that it induced higher geometric mean antibody titers (GMT) and seroconversion rates than the control group, particularly against Type A strains, which exhibit high mutation frequencies and are prone to causing severe disease in the elderly. Because it is synthesized via a cell-free process based on digital sequence information without going through eggs, the risk of artificial antigen modification is fundamentally eliminated.
In terms of the safety profile, transient reactogenicity symptoms such as injection site pain, fatigue, and myalgia predominated, and did not exceed the categories reported in previous mRNA vaccine administration groups. The manufacturing speed—enabling a response within six weeks from the determination of the antigen gene sequence to the production of clinical vaccines—is a metric that existing egg-based vaccines could never achieve.
Significance and Outlook
This approval is seen as a harbinger of a generational shift in the influenza vaccine market. It secures the flexibility to produce customized vaccines after observing mutation data right before a seasonal outbreak, even if circulating strains change rapidly each season. It is a turning point where the paradigm of respiratory infectious disease vaccines shifts from a passive system relying on predictions made months in advance to an active system responding to real-time genomic tracking.
Scalability is also a noteworthy aspect. Leveraging this single flu vaccine approval, Moderna is accelerating the development of combination multivalent vaccines that combine COVID-19 and Respiratory Syncytial Virus (RSV) antigens into a single injection. This can significantly increase vaccination compliance by reducing the burden on elderly patients who otherwise must receive multiple injections every autumn.
On the other hand, practical barriers remain. The cost of cold-chain management, which requires ultra-low or sub-zero distribution environments, is an obstacle to distribution in low- and middle-income countries. The somewhat higher frequency of mild adverse events, such as fever and fatigue, compared with existing inactivated vaccines is also a challenge to be addressed to enhance public acceptance. Full market establishment is expected to be possible once data on long-term immune duration and actual vaccine effectiveness (VE) in subsequent flu seasons are accumulated.
Nature Biotechnology, Published online: 10 September 2026; doi:10.1038/s41587-026-03313-yModerna flu vaccine wins FDA approval
In clinical settings, a pathway is opening to supply precision vaccines with replaced target antigens within just a few weeks, even if mutations occur immediately before the flu season. For nursing home residents or immunocompromised individuals, for whom herd immunity is difficult to achieve, clinical benefits such as a substantial reduction in severe hospitalization and mortality rates can be expected based on the robust antibody response against influenza A virus. In the pharmaceutical industry, the landscape of the respiratory vaccine market is expected to shift rapidly from traditional vaccine manufacturers to synthetic biology-based platform companies as the launch of combination vaccines protecting against both influenza and COVID-19 in a single vial becomes imminent.